Heron Therapeutics, Inc. (NASDAQ:HRTX) has earned an average recommendation of “Buy” from the thirteen ratings firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $30.57.

A number of analysts recently weighed in on HRTX shares. ValuEngine raised shares of Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Heron Therapeutics in a research report on Monday, June 26th. Zacks Investment Research raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Wednesday, July 12th. Jefferies Group LLC reissued a “buy” rating and issued a $26.00 price objective on shares of Heron Therapeutics in a research report on Friday, July 14th. Finally, Aegis reissued a “buy” rating and issued a $33.00 price objective on shares of Heron Therapeutics in a research report on Tuesday, July 18th.

Hedge funds have recently modified their holdings of the business. Legal & General Group Plc grew its stake in Heron Therapeutics by 13.9% in the 1st quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 1,098 shares in the last quarter. Quantbot Technologies LP grew its stake in Heron Therapeutics by 2,619.6% in the 2nd quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock worth $172,000 after acquiring an additional 12,024 shares in the last quarter. HighTower Advisors LLC grew its stake in Heron Therapeutics by 11.4% in the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 1,700 shares in the last quarter. Tudor Investment Corp ET AL bought a new position in Heron Therapeutics in the 1st quarter worth about $253,000. Finally, Voya Investment Management LLC grew its stake in Heron Therapeutics by 44.4% in the 2nd quarter. Voya Investment Management LLC now owns 20,377 shares of the biotechnology company’s stock worth $282,000 after acquiring an additional 6,267 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “Heron Therapeutics, Inc. (HRTX) Given Average Recommendation of “Buy” by Analysts” was published by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/11/heron-therapeutics-inc-hrtx-given-average-recommendation-of-buy-by-analysts-2.html.

Heron Therapeutics (NASDAQ:HRTX) traded down 0.31% during mid-day trading on Wednesday, hitting $16.30. The company had a trading volume of 553,795 shares. The stock has a 50 day moving average price of $16.00 and a 200-day moving average price of $15.17. Heron Therapeutics has a 1-year low of $12.21 and a 1-year high of $20.85. The stock’s market capitalization is $882.45 million.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.10. The firm had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $4.53 million. On average, analysts forecast that Heron Therapeutics will post ($3.51) earnings per share for the current year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.